

**Remarks**

Claims 10, 11, 18 and 19 are pending in this application.

Applicants are taking the opportunity of responding to the Restriction Requirement and Election of Species issued in the Office Action dated November 26, 2007, to rectify an error in the specification. During a review of the specification, it was noted there are two distinct Examples each designated as Example 9 on page 39. Applicants have amended the first occurrence of Example 9 to read 9-1 and the second occurrence of Example 9 to read 9-2. No new matter is believed added by these amendments.

Applicants elect, without traverse, the compounds of Group I as identified in the November 26, 2007 Office Action. Further, Applicants select the single species of Example 29, Claims 10 and 11. Example 29 is the compound N-(4-{4-[2-(3-Phenyl-propylamino)-ethyl]-phenoxy}-phenyl)-acetamide.

Applicants are also taking the opportunity of responding to the Restriction Requirement to amend Claims 10, 11 and 19 to more clearly define aspects of the inventive subject matter disclosed in the present application. In Claim 10, the compound of Example 3 has been added.

In each of Claims 11 and 19, language has been deleted. No new matter is added by the amendments to Claims 10, 11 or 19.

Applicants direct the Examiner's attention to Examples 24-51, 53-58 and 60, at least, as tentatively falling within the scope of Group I.

Applicants believe they have fully responded to the November 26, 2007 Office Action.

Applicants respectfully request favorable consideration of the invention as claimed.

Respectfully submitted,

/John C. Demeter/

John C. Demeter  
Attorney for Applicants  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

November 30, 2007